UNSPSC 51271603: Bupivacaine

This classification denotes an anesthetic agent with the molecular formula C18H28N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y8335394RO, chemically known as 2-piperidinecarboxamide, 1-butyl-n-(2,6-dimethylphenyl)- but generally known as bupivacaine, which bears US NIH Compound Identifier 2474. Bupivacaine most often comes in base and hydrochloride forms. European Medicines Agency schedules Bupivacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05983MIG.

UNSPSC 51271603 Bupivacaine is a Commodity code for local anesthetic injectable pharmaceuticals that state and local procurement systems acquire through multistate cooperative purchasing agreements and direct pharmaceutical supply contracts. The code covers bupivacaine and related local anesthetic agents in injectable forms used across public health systems, hospitals, clinics, and emergency services operated by state and local jurisdictions.

State and local governments procure bupivacaine primarily through cooperative purchasing vehicles administered by state procurement offices and multistate alliances rather than individual jurisdictional RFPs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products spanning participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Vendors must demonstrate compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson), and provide pricing through fixed, net, or WAC-minus formats. The MMCAP RFP due March 26, 2026 emphasizes price competitiveness at 75 percent of evaluation weight, with vendors required to carry $5,000,000 commercial general liability coverage and maintain a minimum six-month shelf life on all products. Contract awards span two years for new vendors with optional extensions through June 30, 2028 for incumbents, with a 3 percent administrative fee on all purchases and performance penalties of $200 to $1,500 per violation. The solicitation does not disclose a specific dollar value or budget range.